. Principal products in this segment include the following: Over-the-Counter Products: Claritin non-drowsy antihistamines; MiraLAX for relief of occasional constipation; Coricidin HBP decongestant-free cold/flu medicine for people with high blood pressure; Afrin nasal decongestant spray; Zegerid OTC treatment for frequent heartburn; and Oxytrol For Women, a treatment for overactive bladder in women. Foot Care: Dr. Scholl’s foot care products; Lotrimin topical antifungal products; and Tinactin topical antifungal products and foot and sneaker odor/wetness products. Sun Care: These products include Coppertone sun care lotions, sprays and dry oils. Joint Ventures The company and Sanofi Pasteur S.A. formed a joint venture to market human vaccines in Europe and to collaborate in the development of combination vaccines for distribution in the then-existing the European Union (the EU) and the European Free Trade Association. The company and Sanofi Pasteur S.A. contributed, among other things, their European vaccine businesses for equal shares in the joint venture, known as Sanofi Pasteur MSD, S.N.C. The joint venture maintains a presence, directly or through affiliates or branches, in Belgium, Italy, Germany, Spain, France, Austria, Ireland, Sweden, Portugal, the Netherlands, Switzerland and the United Kingdom and through distributors in the rest of its territory Distribution The company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as health maintenance organizations, pharmacy benefit managers and other institutions. Human health vaccines are sold primarily to physicians, wholesalers, physician distributors and government entities. The company sells its animal health products to veterinarians, distributors and animal producers. The company’s over-the-counter, foot care and sun care products are sold through wholesale and retail drug, food chain and mass merchandiser outlets, as well as club stores and specialty channels. Research and Development The company’s research and development expenses were $7.5 billion in 2013. The company has various candidates under regulatory review in the United States or internationally. MK-5348, vorapaxar, is an investigational anti-thrombotic medicine under review by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA). In January 2014, the FDA’s Cardiovascular and Renal Drugs Advisory Committee recommended approval of vorapaxar. V503, the company’s nine-valent HPV vaccine in development to help protect against certain HPV-related diseases, is under review by the FDA. MK-8962, corifollitropin alfa injection, is an investigational fertility treatment under review by the FDA for controlled ovarian stimulation in women participating in assisted reproductive technology. MK-7243, Grastek (Timothy Grass Pollen Allergen Extract), an investigational Timothy grass pollen allergy immunotherapy tablet (AIT), and MK-3641, Ragwitek (Short Ragweed Pollen Allergen Extract), an investigational ragweed pollen AIT, are both under review by the FDA. MK-4305, suvorexant, is an investigational insomnia medicine in a new class of medicines called orexin receptor antagonists for use in patients with difficulty falling or staying asleep. MK-8616, sugammadex sodium injection, is an investigational agent for the reversal of neuromuscular blockade induced by rocuronium or vecuronium (neuromuscular blocking agents). MK-8109, vintafolide, is an investigational cancer candidate under review by the EMA. As part of an exclusive license agreement with Endocyte, Inc. (Endocyte), the company is responsible for the development and worldwide commercialization of vintafolide in oncology. MK-7009, vaniprevir, is an investigational, oral twice-daily protease inhibitor for the treatment of chronic hepatitis C virus (HCV) infection under review in Japan. MK-3475, an investigational anti-PD-1 immunotherapy, is being evaluated for the treatment of patients with advanced melanoma and other tumor types. The MK-3475 clinical development progr
merck & co. inc.
(MRK:New York Consolidated)
One Merck Drive
PO Box 100
Whitehouse Station, NJ 08889
|Bayer AG||€112.01 EUR||+5.69|
|GlaxoSmithKline PLC||1,437 GBp||+2.50|
|Pfizer Inc||$30.58 USD||+0.23|
|Roche Holding AG||SFr.283.30 CHF||+2.50|
|View Industry Companies|
Sponsored Financial Commentaries
To contact MERCK & CO. INC., please visit www.merck.com. Company data is provided by Capital IQ. Please use this form to report any data issues.